Drugs / Epoetin beta pegol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02791763 Comparator | Jun 2016 → Oct 2018 | anemia | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epoetin beta pegol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02791763 ↗ |
| Route | Subcutaneous | “Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.” NCT02791763 ↗ |